Tyler Technologies (TYL) Q1 Net Margin Stability Tests Bullish Profit Expansion Narrative

Tyler Technologies (TYL) opened 2026 with Q1 revenue of US$613.5 million and basic EPS of US$1.90, alongside net income of US$81.2 million, setting a clear benchmark for how the year is starting to shape up. The company has seen quarterly revenue move from US$565.2 million in Q1 2025 to US$613.5 million in Q1 2026, while basic EPS shifted from US$1.88 to US$1.90 over the same period, giving investors a clean view of how sales and earnings are tracking into the new year. With trailing twelve month net income of US$315.7 million and margins holding in the low teens, this latest print puts the focus squarely on how efficiently Tyler is converting revenue into profit.

See our full analysis for Tyler Technologies.

With the headline numbers on the table, the next step is to see how they compare with the widely held narratives about Tyler’s growth, profitability, and long term trajectory.

See what the community is saying about Tyler Technologies

NYSE:TYL Revenue & Expenses Breakdown as at May 2026
NYSE:TYL Revenue & Expenses Breakdown as at May 2026
Advertisement

Margins Steady Around 13.3%

  • Over the last 12 months, Tyler posted net income of US$315.7 million on US$2.38b of revenue, which works out to a net margin of about 13.3% compared with 13.2% the year before.
  • Bulls point to this steady margin as support for their view that profit margins can climb to 18.1% in a few years. The data also show that trailing 12 month earnings growth of 8.9% sits below the 16.1% annual pace of the past five years, which means:
    • The bullish margin target implies a clear step up from the current 13.3%, even though recent profitability has only nudged higher.
    • With net income holding around US$315.7 million over the past year, the bullish case is asking for a sizable jump from today’s earnings base.
Over the last year of solid but slower profit growth, bulls argue this stable 13.3% margin is the platform for a much higher earnings run rate, and you can see how they build that case in the 🐂 Tyler Technologies Bull Case.

Premium 45.9x P/E Against Slower Growth

  • The stock trades on a 45.9x P/E, above both the US Software industry at 29.1x and peers at 38.9x, while trailing 12 month earnings growth of 8.9% is below the 16.1% annual rate seen over the last five years.
  • Bears focus on this combination of a premium multiple and moderating growth, arguing it bakes in high expectations. The current numbers give them some support because:
    • Forecast annual earnings growth of about 14.75% and revenue growth of 7.9% are both below the broader US market expectations of 16.1% for earnings and 11% for revenue.
    • The 45.9x P/E therefore sits above industry and peer averages even though the growth outlook is described as slower than the wider market, which is the core of the cautious view.
With the share price near US$341.14 and a P/E above sector averages while growth is expected to trail the market, skeptics see a lot already priced in, and their arguments are laid out in the 🐻 Tyler Technologies Bear Case.

DCF Gap Versus 441.10 Target

  • The current share price of about US$341.14 sits below both a DCF fair value estimate of roughly US$431.75 and an analyst price target reference of US$441.10, highlighting a valuation gap on both metrics.
  • Consensus narrative supporters point out that this gap lines up with a long runway in recurring revenue and AI and cloud opportunities. The figures also show some tension because:
    • Analysts expect revenue growth of 8.9% a year and margins rising from about 13.5% to 16.6%, which need to materialize to justify a price closer to US$441.10.
    • At the same time, the 45.9x P/E and below market growth forecasts mean any shortfall versus those revenue or margin expectations could keep the share price closer to current levels than to the DCF fair value or target.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Tyler Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment clearly split between opportunity and caution, this is the moment to look through the numbers yourself and decide where you stand. To weigh up both sides in detail, start with these 3 key rewards and 1 important warning sign.

See What Else Is Out There

Tyler’s premium 45.9x P/E, paired with earnings and revenue growth expectations that sit below broader market levels, leaves limited room for disappointment.

If that mix feels tight for your risk tolerance, this is a good moment to compare it with companies screened as attractively priced using the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Tyler Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:TYL

Tyler Technologies

Provides integrated software and technology management solutions for the public sector in the United States.

Flawless balance sheet and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
66 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
CSBT.F logo
AnimalDoctorKwon on Kuros Biosciences ·

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

Fair Value:US$342.1892.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
RZLV logo
European_Hidden_Gem_Stocks on Rezolve AI ·

⚡ Two-Minute Drill: Rezolve AI - The AI That Doesn't Recommend Products. It Buys Them.

Fair Value:US$80.7897.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0